Advanced searches left 3/3

Ace Inhibitor - Crossref

Summarized by Plex Scholar
Last Updated: 10 June 2022

* If you want to update the article please login/register

Purification and Identification of an ACE-Inhibitory Peptide from Gracilaria tenuistipitata Protein Hydrolysates

"Edible marine animals are valuable sources of bioactive peptides. " The hydrolysate GTN4H was found to be the first ACE-inhibitory activity in vitro, with two separate proteolytic reactions for 2 u201310 h. In addition, oral administration of GTN4H has significantly reduced systolic blood pressure in spontaneously hypertensive rats. ".

Source link: https://doi.org/10.3390/pr10061128


Significant Suppressive Effect of Low-Dose Temocapril, an ACE Inhibitor with Biliary Excretion, on FGS Lesions in Hypertensive Rats

"On the other hand, although a small dose of TEM did not dramatically lower BP during the trial period, it did not prevent renal lesions in the same way as high-dose TEM with suppression of c-myc gene expression in glomeruli. " The systemic BP elevation in PAN-induced chronic FGS could not be the cause of renal impairment, according to these results, which TEM could prevent without significant lowering of BP. ".

Source link: https://doi.org/10.1159/000045839


Aspirin and ACE Inhibitors in Patients with Heart Failure: WATCHing for a Potential Interaction

"Coronary artery disease is the leading cause of chronic heart disease, and a substantial number of patients with left ventricular dysfunction are treated with aspirin. " Angiotensin-converting enzyme inhibitors have emerged as the gold therapy for patients with symptomatic and asymptomatic LV dysfunction. The coadministration of aspirin has shown that in patients with LV dysfunction, the beneficial effects of ACE inhibitors on hemodynamic measures of systemic vascular resistance, cardiac output, and LV filling pressures are greatly reduced by aspirin coadministration. There is an growing body of retrospective clinical trial evidence indicating that these hemodynamic factors may translate into a reduction in the mortali-ty benefit seen in ACE inhibitor-treated patients not receiving aspirin. "The Warfarin Antiplatelet Therapy in Chronic Heart Failure trial, an ongoing study that will explore the issue of the correct antithrombotic therapy for patients with persistent heart failure, will be discussed. ".

Source link: https://doi.org/10.1159/000048955


Beneficial Effect of the Long-Term Treatment with the Combination of an ACE Inhibitor and a Calcium Channel Blocker on Renal Injury in Rats with 5/6 Nephrectomy

"The effects of the addition of a calcium channel blocker, verapamil to an ACE inhibitor, trandolapril, in a 6-month treatment for renal insufficiency development in rats with 5/6th nephrectomy were investigated. " In rats treated with the combination of verapamil and trandolapril, no mortality was recorded. The combination verapamil-trandolapril did not result in any decrease in blood pressure. The renal injury investigators' light microscopy semiquantitative experiments revealed that the trandolapril and verapamil + trandolapril groups had a dramatic decrease in glomerular and tubulointerstitial alterations, compared to untreated animals. When rats were treated with trandolapril and even more with verapamil+ trandolapril and even more on untreated animals, their fibrosis was reduced, according to quantitative analyses of glomerular and interstitial fibrosis, compared to untreated animals' u2019 values. In summary, long-term therapy with verapamil in lieu of trandolapril provides more safeguard against progressive renal disease linked to subpartial nephrectomy. ".

Source link: https://doi.org/10.1159/000020503


ACE Inhibitors Suppress Ischemia-Induced Arrhythmias by Reducing the Spatial Dispersion of Ventricular Repolarization

"In 12 pentobarbitone-anesthetized sheep, the effect of angiotensin-converting enzyme inhibitors on ischemia-induced spatial dispersion of ventricular repolarization was investigated. " In both groups at 30 minutes of coronary occlusion, there was a significant rise in the pooled activation-recovery interval dispersion in both groups, but the change in the treatment group was smaller than that in the controls. In the 6 experiments and in only 1 pretreated animal, only one ectopic beats were recorded. ".

Source link: https://doi.org/10.1159/000006956


Antihypertensive Treatment in Postmenopausal Women: Results from a Prospective, Randomized, Double-Blind, Controlled Study Comparing an ACE Inhibitor (Moexipril) with a Diuretic (Hydrochlorothiazide)

"The current research was designed to compare the safety and effectiveness of the new angiotensin-converting enzyme inhibitor moexipril with that of hydrochlorothiazide in postmenopausal women with mild-to-moderate hypertension. " 97 postmenopausal hypertensive women with a sitting diastolic blood pressure of 95-mm Hg were randomly assigned to either daily moexipril 15 mg or HCTZ 25 mg for a 12-week double-blind clinical trial period. In postmenopausal women, moexipril was better tolerated than HCTZ in postmenopausal women and did not adversely influence metabolic characteristics," the study revealed.

Source link: https://doi.org/10.1159/000006799


Is the Tissue Affinity of ACE Inhibitors of Relevance for the Remodeling of the Left Ventricular Wall following Myocardial Infarction?

"The question whether drugs with a greater tissue affinity are associated with health and endurance are, however, remains unclear. " Aim: The aim of the present research was to investigate the effect of ACE inhibitors with differing tissue affinities on the remodeling of the left ventricular wall in patients recovering from myocardial infarction. Methods: 52 patients suffering from acute myocardial infarction were selected to receive either 25 mg captopril or 10 mg fosinopril daily, beginning on the 7th postinfarction day. An anterior wall infarction was found in 28 patients, and 24 patients had an inferior wall infarction. The following parameters were established: infarct weight and diastolic diameter of the infarcted zone, systolic wall strain, muscle mass, diastolic and systolic wall thickness, systolic wall thickness, and motility of the noninfarcted myocardium. The infarct weight gain under captopril was 5. 7% and under fosinopril by 6. 1%. Under captopril and by 15. 4% and 9. 6%, respectively under fosinopril, the systolic wall thickness increased by 12. 1% and the muscle mass increased by 12. 7%. For all parameters, the results obtained in anterior wall infarction were appreciably poorer than those obtained in inferior wall infarction. All the similarities between captopril and fosinopril were not significant. Conclusions: Following myocardial infarction, both captopril and fosinopril demonstrated no significant differences in their influence on left ventricular wall reconstruction. The tissue affinity of an ACE inhibitor does not appear to be of a significant concern for post-infarction therapy, according to the present study.

Source link: https://doi.org/10.1159/000047314


Combination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic Nephropathy

"The benefit of angiotensin II therapy in diabetic glomerular hemodynamics, hypertrophy, and tissue fibrosis is thought to be largely due to attenuation of angiotensin II's effects on blood pressure, glomerular hemodynamics, and hypertrophy" in diabetic glomerulosclerosis. The present research was conducted to see if extending AngII receptor antagonist therapy to ACEi therapy in diabetic nephropathy results in attenuation of AngIII symptoms that were not expected by ACEi alone. Mean renin values during combination therapy increased dramatically during combination therapy and then returned to baseline values after discontinuation of AT1a therapy, 3. 9 ng/ml/min u00b1 2. 0 u00b1 2. 0 SE. "In diabetic nephropathy patients with AT1a therapy to ACEi therapy, we find that AngII therapy has better results than ACEi therapy alone. ".

Source link: https://doi.org/10.1159/000013417


ACE inhibitors/ARB and the risk of breast cancer recurrence after surgery in Japanese population: A pilot study.

"52 Background: Angiotensin II may act as a growth promoter by angiotensin II type 1 receptor. The results are not consistent in several clinical studies; however, in some scientific studies, the safety of ACEI/ARB to cancer patients has been investigated; however, the results are not consistent. If the recurrence rate is related to ACEI/ARB use, we investigated breast cancer patients in a joint center. Methods: This retrospective review will explore disease-free survival of Japanese patients who were diagnosed with invasive breast cancer and had curative surgery at St Luke's International Hospital between January 2004 and December 2006 will explore disease-free survival for Japanese patients. DFS stands for the period between curative surgery and breast cancer recurrence. Patients who received ACEI/ARB after initial diagnosis were categorized as those who received them for at least six months after initial diagnosis. "Our research was the first one to determine the safety of ACEI/ARB in breast cancer recurrence among Asian populations," our report finds.

Source link: https://doi.org/10.1200/jco.2012.30.27_suppl.52

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions